Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Total Debt (2016 - 2023)

Historic Total Debt for Alaunos Therapeutics (TCRT) over the last 4 years, with Q1 2023 value amounting to $11.0 million.

  • Alaunos Therapeutics' Total Debt fell 5481.16% to $11.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $11.0 million, marking a year-over-year decrease of 5481.16%. This contributed to the annual value of $16.8 million for FY2022, which is 3048.76% down from last year.
  • According to the latest figures from Q1 2023, Alaunos Therapeutics' Total Debt is $11.0 million, which was down 5481.16% from $16.8 million recorded in Q4 2022.
  • Over the past 5 years, Alaunos Therapeutics' Total Debt peaked at $24.5 million during Q2 2022, and registered a low of $11.0 million during Q1 2023.
  • Its 3-year average for Total Debt is $21.1 million, with a median of $24.1 million in 2021.
  • Its Total Debt has fluctuated over the past 5 years, first tumbled by 637.31% in 2022, then crashed by 5481.16% in 2023.
  • Quarter analysis of 3 years shows Alaunos Therapeutics' Total Debt stood at $24.1 million in 2021, then tumbled by 30.49% to $16.8 million in 2022, then crashed by 34.46% to $11.0 million in 2023.
  • Its last three reported values are $11.0 million in Q1 2023, $16.8 million for Q4 2022, and $22.7 million during Q3 2022.